All publications

Export 167 results:
Author Title Type [ Year(Asc)]
2017
Volz E, Le Vu S, Ratmann O, Tostevin A, Delpech V, Brown A, Gill NO, Fraser C.  2017.  Phylodynamic analysis to guide allocation of Pre-Exposure Prophylaxis in the United Kingdom. 24th International HIV Dynamics and Evolution.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. BHIVA Spring.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.
2016
Le Vu S, Ratmann O, Delpech V, Brown A, Gill NO, Tostevin A, Fraser C, Volz E.  2016.  Characterising HIV transmission risk factors using genetic source attribution and phylogenetic clustering. HIV Dynamics and Evolution Meeting 2016.
Ragonnet-Cronin M, Shilaih M, Günthard HF, Hodcroft E, Boni J, Fearnhill E, Dunn DT, Yerly S, Klimait T, Aubert V et al..  2016.  A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Sci Rep. 6
TenoRes Study Group.  2016.  Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis.
El-Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak A, Tostevin A, Pillay D, Dunn DT et al..  2016.  HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 71(12)
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. International HIV Drug Resistance Workshop 2016.
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
De Luca A., Flandre P., Dunn DT, Zazzi M, Wensing A., Santoro MM, Günthard HF, Wittkop L., Kordossis T., Garcia F. et al..  2016.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.
Antiretroviral Therapy Cohort Collaboration(ART-CC), Canadian Observational Cohort Collaboration(CANOC), UK Collaborative HIV Cohort Study(UK CHIC), Collaboration of Observational HIV Epidemiological Research in Europe(COHERE).  2016.  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3)
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin CA, Pillay D, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2016.  No Effect of HIV-1 Subtype C on Virological Failure Rate with First-line TDF Regimens. International HIV Drug Resistance Workshop 2016.
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin CA, Pillay D, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2016.  No Effect of HIV-1 Subtype C on Virological Failure Rate with First-line TDF Regimens. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin CA, Pillay D, Dunn DT, UK HIV Drug Resistance Database et al..  2016.  No evidence that HIV-1 subtype C infection compromises the efficacy of Tenofovir-containing: Cohort study in the United Kingdom. J Infect Dis.
Hue S, Villanueva RMucio, Tostevin A, Delpech V, Pozniak A, Ashton L, Pillay D, Goldstein R, UK HIV Drug Resistance Database.  2016.  Probabalistic Estimation of HIV-1 Subtype B Transmission Rates from Viral Phylogenies. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
Tostevin A, White E, Dunn DT, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A, Churchill D, Geretti AM et al..  2016.  Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Med.
Ragonnet-Cronin M, Lycett S, Hodcroft E, Hue S, Fearnhill E, Brown A, Delpech V, Dunn DT, Leigh Brown A.  2016.  Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis. 213:1410-8.
Jose S., Quinn K., Dunn DT, Cox A., Sabin CA, Fidler S.  2016.  Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Med. 17:368-72.
2015
Byrne L, Thorne C, Tookey P, Tostevin A, Dunn DT, Chau C, Delpech V.  2015.  Antiretroviral drug resistance in pregnant women living with HIV in England and Wales: Preliminary results from the matching of three national HIV surveillance databases. British HIV Association Conference (BHIVA) 2015.
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane P A.  2015.  Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. Clin Infect Dis. 61:829-36.